View in EDS

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Saved in:
Bibliographic Details
Title: Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.
Authors: Derbala MH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hwang W; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Ock CY; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Hwang S; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Hajjar J; Division of Immunology, Allergy and Retrovirology, Baylor College of Medicine, Houston, Texas, USA., Lee S; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Zhou J; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gurses SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McGonagle KE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alshawa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Castillo L; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zarifa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Solis Soto LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Raso MG; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ali S; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA anaing@mdanderson.org.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jun 24; Vol. 14 (6). Date of Electronic Publication: 2026 Jun 24.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42342409
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Derbala+MH%22">Derbala MH</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Stephen+B%22">Stephen B</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Hwang+W%22">Hwang W</searchLink>; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of).<br /><searchLink fieldCode="AU" term="%22Ock+CY%22">Ock CY</searchLink>; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of).<br /><searchLink fieldCode="AU" term="%22Hwang+S%22">Hwang S</searchLink>; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of).<br /><searchLink fieldCode="AU" term="%22Hajjar+J%22">Hajjar J</searchLink>; Division of Immunology, Allergy and Retrovirology, Baylor College of Medicine, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Lee+S%22">Lee S</searchLink>; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of).<br /><searchLink fieldCode="AU" term="%22Zhou+J%22">Zhou J</searchLink>; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Gurses+SA%22">Gurses SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Gouda+MA%22">Gouda MA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22McGonagle+KE%22">McGonagle KE</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Alshawa+A%22">Alshawa A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Castillo+L%22">Castillo L</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Zarifa+A%22">Zarifa A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Solis+Soto+LM%22">Solis Soto LM</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Raso+MG%22">Raso MG</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Ali+S%22">Ali S</searchLink>; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of).<br /><searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA anaing@mdanderson.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2026 Jun 24; Vol. 14 (6). <i>Date of Electronic Publication: </i>2026 Jun 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42342409
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2025-014768
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Derbala MH
      – PersonEntity:
          Name:
            NameFull: Stephen B
      – PersonEntity:
          Name:
            NameFull: Hwang W
      – PersonEntity:
          Name:
            NameFull: Ock CY
      – PersonEntity:
          Name:
            NameFull: Hwang S
      – PersonEntity:
          Name:
            NameFull: Hajjar J
      – PersonEntity:
          Name:
            NameFull: Lee S
      – PersonEntity:
          Name:
            NameFull: Zhou J
      – PersonEntity:
          Name:
            NameFull: Gurses SA
      – PersonEntity:
          Name:
            NameFull: Gouda MA
      – PersonEntity:
          Name:
            NameFull: McGonagle KE
      – PersonEntity:
          Name:
            NameFull: Alshawa A
      – PersonEntity:
          Name:
            NameFull: Castillo L
      – PersonEntity:
          Name:
            NameFull: Zarifa A
      – PersonEntity:
          Name:
            NameFull: Fu S
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Tsimberidou AM
      – PersonEntity:
          Name:
            NameFull: Meric-Bernstam F
      – PersonEntity:
          Name:
            NameFull: Solis Soto LM
      – PersonEntity:
          Name:
            NameFull: Raso MG
      – PersonEntity:
          Name:
            NameFull: Ali S
      – PersonEntity:
          Name:
            NameFull: Naing A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 06
              Text: 2026 Jun 24
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1